Zevra Therapeutics reported a 53% year-over-year revenue increase in the second quarter of 2026, reaching $39.7 million, largely driven by $30.2 million from its rare disease drug Miplyffa. The company shows early signs of profitability and strong patient retention, suggesting a sustainable business model. Management is expanding diagnosis efforts, potentially increasing the treatable patient population to 900, which could extend growth prospects. Risks include heavy dependence on Miplyffa, uncertain European drug approval, and variable early access program revenues, but the stock remains attractively valued compared to peers.
Zevra Therapeutics' recent revenue growth and business outlook provide context for health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Oct 06, 2026 15:41 WIB: Out of 100 priced US health-sector stocks tradable on Pluang, 68 rose and 27 fell today. Notable movers include AMPH at USD 25.03 with a 1-day change of -1.34% and a typical hold time of 16 days, PHG at USD 24.23 with a 1-day change of +1.34% and Pluang order activity showing 0% Sell / 100% Buy with a typical hold time of 83 days, and AZN at USD 158.60 with a 1-day change of +1.32% and Pluang order activity of 5% Sell / 95% Buy with a typical hold time of 126 days.
Over the past six months, Costco's stock has fallen by 10%, contrasting with the S&P 500's 17% gain. This decline has sparked debate on whether Costco's shares, now trading under $900, represent a buying opportunity. Investors are weighing if the pri...
Elon Musk has confirmed that his company is in discussions with Terafab, marking a potential new chip manufacturing partner alongside Intel, which has been the only named chip partner until now. This development could diversify the supply chain and e...
Garmin has introduced the Enduro 4, its longest-lasting GPS smartwatch featuring solar charging and up to 320 hours of battery life in activity mode. Designed for endurance athletes and adventurers, it includes advanced features like grade-adjusted p...
Ondo Finance has launched Ondo Private Markets, a platform offering tokenized notes linked to the value of shares in a pre-IPO AI company. These notes provide economic exposure without ownership or voting rights and will trade 24/7 on secondary marke...
Stellar's network saw tokenized assets surpass $3 billion and stablecoin transfer volume reach a record $11.4 billion in Q2 2026, signaling strong real-world financial use. Despite XRP's larger market cap and institutional presence, Stellar's smaller...
